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Objectives: An alginate oligosaccharide (OligoG) solution for nebulisation has
completed phase 2a for treatment of cystic ﬁbrosis. The objective of the current
study was to assess the systemic and local toxic potential of a newly developed
OligoG dry powder for inhalation (DPI) in a 4-week inhalation study in rats.
Methods: Conscious rats (n = 142) were dosed once daily for 28 days in a snout-only
ﬂow-past inhalation exposure chamber with test aerosols delivered by a Rotating
Brush Generator providing OligoG doses up to 467mg/kg/day. Serial investigations
were performed to monitor any treatment related effects.
Results: No clinical signs or treatment related effects were observed on bodyweight,
food consumption, ophthalmoscopy or haematology. Dose related ﬁndings included
high lung weights, pale areas and alveolar macrophages/macrophage debris in
the lungs, and enlarged tracheobronchial lymph nodes with increased cellularity
in some rats in all treated groups. After 4 weeks of recovery for high dose
animals, previously slightly elevated blood phosphorous and urinary pH values,
were normalised. Furthermore, all animals fully recovered from the ﬁndings in the
lymph nodes and partially recovered from the ﬁndings in the lungs. Similar to
the nebulised solution, all histology ﬁndings were considered to be consequences
of normal clearance mechanisms and therefore not adverse. Toxicokinetic data
demonstrated low uptake and efﬁcient plasma clearance of the OligoG.
Conclusion: Inhalation of OligoG DPI up to for 28 days was well tolerated without
signs of adverse toxicity. Based on this study, 467mg OligoG/kg/day is considered
to be the No Observed Adverse Effect Level (NOAEL).
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Objectives: Alginate oligosaccharide solution (OligoG) has been shown to disrupt
bacterial bioﬁlms in vitro and reduce elevated mucus viscosity in ex vivo CF sputum.
We have now studied the safety and tolerability of multiple OligoG administrations
for the ﬁrst time in CF patients.
Methods: Using a multicentre, randomised, double-blind, placebo-controlled (nor-
mal saline), cross-over protocol we performed a phase 2a clinical trial of nebulised
OligoG. Twenty-six adult CF patients (all chronically colonised with P. aeruginosa,
screening FEV1 35−80% predicted), inhaled 540mg OligoG or placebo daily
via the SidestreamPlus/Portaneb aerosol delivery system in two 28-day study
periods separated by a 4-week washout. Safety, tolerability and exploratory efﬁcacy
outcomes on sputum rheology (Discrete Relaxation Times Spectrum Analysis), lung
function and health-related quality-of-life (QoL) were assessed.
Results: OligoG showed an adverse event proﬁle similar to placebo, with ﬁndings
primarily related to the underlying CF disease. No differences in spirometry or
QoL were found. However, in a subset of 10 patients who produced samples of
sufﬁcient quality for rheology, 7 patients had improved sputum ﬂuidity during
OligoG treatment, compared to only 1 patient on placebo.
Conclusion: Repeated inhalation of nebulised OligoG solution was safe and well
tolerated in CF patients, and conﬁrms the favourable safety proﬁle seen in a previous
healthy volunteer study. The observed rheology effects give promise for OligoG in
upcoming dose-ﬁnding phase 2b studies.
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The antimicrobial, antibioﬁlm and mucoactive properties of Lynovex®, an orphan
drug candiate treatment for cystic ﬁbrosis (CF) have previously been demonstrated
in vitro (Charrier et al., ECFS, 2012).
We now add further evidence of its clinical potential by demonstrating that
Lynovex® signiﬁcantly reduces and in some cases eradicates the complex antibiotic-
resistant (poly)microbial burden of freshly isolated sputum from CF patients; a
high-dose single (24 h) exposure to Lynovex® ex vivo or low dose repeat exposure
over a 14 day period achieving this effect. This reduction in sputum derived CFU
(21 patients took part in the study) was enhanced when Lynovex® was exposed
to sputum in combination with tobramycin. Lynovex® outperformed currently
available mucoactive agents in its macrorheological impact on CF sputum.
Lynovex® is being developed as an orally available and inhaled CF therapeutic, for
acute exacerbations and long term treatment/maintenance and the data shown here
supports its potential as a ﬁrst-in-class, tri-functional (antimicrobial-antibioﬁlm-
mucolytic) treatment for CF.
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Objective and Background: Although pancreatic enzyme therapy is life-saving
for patients with Cystic Fibrosis, there may be suboptimal absorption of fats and
critical fatty acids, especially in patients receiving tube feedings and nutritional
drinks (ND). A novel point of care lipase, ALCT-460, was developed to efﬁciently
pre-hydrolyze triglycerides (TG) speciﬁcally omega 3 and 6, to absorbable fatty
acids ex vivo, just prior to use. We sought to determine whether pre-hydrolyzed
formula given to EPI pigs enhances absorption and tissue incorporation of critical
long chain polyunsaturated fatty acids (LCPUFA).
Methods: 3-month old EPI pigs were fed 4x day with formula non-hydrolyzed
(n = 4) or pre-hydrolyzed (n = 4) with ALCT-460 (325u/31g fat) for 15 minutes
which results in 80% hydrolysis of TG in vitro. The formula used was NAN (Nestle)
fortiﬁed with TG-docosahexaenoic acid (DHA) and TG-arachidonic acid (AA) for
7 days. Plasma and tissue fatty acid levels were analyzed by GC-MS.
Results: Pre-hydrolyzed formula containing 120g of fat was well-tolerated and safe.
Total CFA increased from 67% to 87%. Fecal DHA and AA decreased by 57% and
62% respectively resulting in DHA and AA increases in plasma (30% and 58%),
heart (40% and 65%) and retina (249% and 210%), respectively.
Conclusions: Pre-hydrolyzed formula is well-tolerated and readily absorbed leading
to reduced fecal fatty acid losses. This was associated with higher systemic and
tissue levels of DHA and AA, both important in infant growth and development.
Thus, ALCT-460 may represent an effective approach to patients with CF to
optimize fat hydrolysis, LCPUFA incorporation and caloric intake from ND or
during tube feeding.
